Munich, Germany – 26th November 2024 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
News
News
Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer
admin
/ November 26, 2024
Touchlight, Cell and Gene Therapy Catapult and Complement Therapeutics to develop innovative manufacturing process for gene therapies
admin
/ May 9, 2024
Munich, Germany – 9th May 2024 – The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation...
Read More
Complement Therapeutics Announces the Establishment of Medical Advisory Board
admin
/ December 14, 2023
Munich, Germany – 14th December 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Appoints Dr. Matthias Hebben, as Chief Technology Officer
admin
/ December 5, 2023
Munich, Germany – 5th December 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
admin
/ November 9, 2023
Munich, Germany – 09 November 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer
admin
/ August 3, 2023
Munich, Germany – 3rd August 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Unveils State-of-the-Art Laboratory at Stevenage Bioscience Catalyst
admin
/ June 13, 2023
Munich, Germany – 13th June 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Appoints Dominic Moreland as Chief Financial Officer
admin
/ April 27, 2023
Munich, Germany – 27th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics to Present Preclinical Proof of Concept Data on CTx001 at the 2023 Association for Research in Vision and Ophthalmology Congress
admin
/ April 20, 2023
Munich, Germany – 20th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases
admin
/ April 17, 2023
Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising...
Read More
Complement Therapeutics Announces Strategic Manufacturing Collaboration with Pharmaron
admin
/ March 29, 2023
London, UK - March 29th 2023 - Complement Therapeutics Ltd (CTx) and Pharmaron are delighted to announce a strategic partnership...
Read More
Complement Therapeutics Enrols First Patient in Non- interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
admin
/ February 9, 2023
London England – 09 February 2023 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced enrolment of...
Read More
Complement Therapeutics secures Innovate UK EDGE funding to collaborate with the Cell and Gene Therapy Catapult on regulatory strategy for CTx001
admin
/ November 17, 2022
The Innovate UK EDGE grant funding is awarded to innovative companies looking to benefit from the expertise provided by Catapults...
Read More
MHRA awards Complement Therapeutics Innovation Passport for CTx001 to accelerate Gene Therapy for Geographic Atrophy
admin
/ November 1, 2022
MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP)ILAP is designed to...
Read More
Complement Therapeutics Announces the Establishment of its Clinical & Scientific Advisory Board
admin
/ September 27, 2022
London, England – 27th September 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced the formation...
Read More
Complement Therapeutics Ltd announces appointment of Dr Dennis Keefe as Chief Scientific Officer
admin
/ August 10, 2022
London, England – 10th August 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research...
Read More
Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors
admin
/ July 18, 2022
Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors London, England – 18th July 2022 -...
Read More
Complement Therapeutics Ltd raises EUR 5 Million Seed Financing by BGV and Forbion and appoints Dr Rafiq Hasan as CEO
admin
/ February 23, 2022
Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases Company emerges out of stealth mode...
Read More